Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway. The gene discussed is ADIPOR1; the disease is metabolic dysfunction-associated steatotic liver disease.